Biotech Startups

Latus develops gene therapies based on novel AAV capsid variants matched to optimized routes of administration, aiming to target specific cell types and tissues to lower dose requirements, toxicity, and manufacturing costs. It focuses on treating monogenic diseases affecting the central nervous system and peripheral tissues using computational methods and unbiased capsid screening.

5 investors

Laverock Tx is a biotechnology company working in the gene therapy and gene editing space, with a leadership and advisory team drawn from cell and gene therapy, immunology, and life-science investing backgrounds.

5 investors

LifeSprout develops synthetic materials that mimic the body's own tissues for aesthetic and regenerative medicine, creating products to treat patients with soft tissue loss from aging, cancer, and metabolic disease. It operates in the regenerative medicine and biomaterials category.

5 investors

Ligandal develops precision medicine targeting technology, including its Peptide Direct Conjugate (PDC) platform driven by LigandAI and Predictive Interactomics, to guide therapeutics to specific disease sites at the molecular level. The company positions its technology as an enabling delivery layer for next-generation, molecularly and genomically precise therapeutics.

5 investors

Light Line Medical develops visible light technology for catheters that reduces infections and improves patient outcomes in minimally invasive medical procedures. The company serves healthcare providers and patients requiring catheter-based treatments across organ, vascular, and lymphatic systems.

5 investors

Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale. It serves therapeutics discovery and development, including antibody, cell therapy, immunotherapy, and regenerative medicine research.

5 investors

Lucira Health (Diassess Inc.) develops low-cost, disposable diagnostic hardware for infectious disease testing that pairs with smartphones to provide rapid, real-time analysis of bodily fluids. The company targets consumer and clinical health diagnostics.

5 investors

Lygos was a performance materials company that used proprietary biology and chemistry to develop sustainable, high-performance ingredients and polymers. It scaled manufacturing and commercialized products across agriculture, cleaning, personal care, and other specialty-materials markets before concluding through two strategic sales.

5 investors

LynxBio (Lynx Biosciences) is a biotech company developing immuno-oncology and immunology therapies using a proprietary patient-based ex vivo disease biology platform combined with a multiomics approach for drug discovery. It partners with biopharmaceutical and technology companies to identify therapeutic candidates while advancing its own internal pipeline.

5 investors

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.

5 investors

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network. The site serves as a landing page directing visitors to the two separate pharmaceutical companies.

5 investors

Manas AI is an AI-native biopharmaceutical company that uses neuro-symbolic foundational models to discover and develop medicines. The company serves the pharmaceutical industry with AI-driven drug discovery and development.

5 investors

Mango Materials develops biopolymers and biocomposites as sustainable alternatives to conventional plastics for consumer and industrial applications. The company focuses on creating environmentally-friendly materials sourced from natural processes.

5 investors

Mango Sciences works with healthcare providers in emerging markets to collect and analyze clinical patient data from underrepresented populations, building a base of real-world evidence and global health data. Its data analytics platform, paired with a patient affordability and accessibility initiative, aims to generate healthcare insights that improve patient access and care.

5 investors

Manifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.

5 investors

Manifold provides an enterprise agent platform that uses agentic AI to accelerate drug discovery and development processes for life sciences companies, from early discovery through clinical stages.

5 investors

MantleBio provides a data management and analytics platform designed for biotech researchers and scientific teams. The platform integrates biological data, enables advanced bioinformatics analysis, and accelerates drug development and genomics research workflows.

5 investors

5 investors

Meatly partners with pet food brands to develop nutritionally formulated, safe, and sustainable pet food products, scaling production toward broader market availability within 3-5 years.

5 investors

Medcura develops hemostatic products made from hydrophobically modified biopolymers to control minimal, mild, and moderate surgical bleeding through mechanical mucoadhesion. Its offerings target surgeons, patients, and payers in the surgical hemostasis market, including specialized applications such as spine surgery.

5 investors

MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds. Its products include NexoBrid, an approved therapy for severe thermal burns, and EscharEx, a candidate for debridement of chronic and hard-to-heal wounds, serving hospitalized and wound care patients worldwide.

5 investors

Medrio provides a no-code electronic data capture (EDC) platform for clinical trials, aimed at small and scaling life sciences sponsors and CRO teams. The platform lets teams configure and manage studies without programming, and offers services from clinical experts covering database build, data management, and biostatistical analysis.

5 investors

Lite Strategy, Inc. (NASDAQ: LITS) is a publicly traded treasury company that accumulates and manages Litecoin (LTC) holdings, aiming to increase LTC exposure per share for its shareholders. It positions itself as a way for public-market investors to gain exposure to Litecoin.

5 investors

Microharvest produces fermentation-derived microbial protein ingredients for use in pet food, aquafeed, and future human food applications. The company focuses on sustainable, GMO-free, allergen-free protein with a complete amino acid profile and micronutrients.

5 investors